Compare Biogen Inc (BIIB) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Robinhood Markets, Inc. — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Robinhood Markets, Inc. trades at $95.15 (market cap $84.86B). The key difference: Robinhood Markets, Inc. is far larger — about 2.8× Biogen Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.
| BIIB | HOOD | |
|---|---|---|
Market Cap | $30.13B | $84.86B |
Sector | Health | Technology |
52-Week High | $216.63 | $152.46 |
52-Week Low | $128.93 | $65.16 |
Enterprise Value | $37.20B | $91.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Robinhood Markets (HOOD) trades at $95.19, up 0.71% on the day, with the stock showing strong fundamental momentum despite a bearish technical signal. The company reported impressive 2025 results with $4.47B revenue and $1.88B net income, representing 42% net margins. Recent Q2 2026 earnings beat expectations with $0.62 EPS versus $0.44 expected, though technical indicators show resistance near $95-97 levels with RSI suggesting potential overbought conditions.
HOOD presents a compelling growth story with 73% analyst buy ratings and a $123.46 consensus price target representing 30% upside potential. Key opportunities include international expansion and product diversification beyond crypto, while risks involve competitive pressures and market volatility sensitivity. The company's transition to profitability and strong cash flow generation support long-term bullish thesis despite near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
